Table 5 Sensitivity analysis

Sorafenib, monthly cost (US$)

1714.29

1371.43–2057.14

342.86

Gamma

Lenvatinib, monthly cost (US$)

2947.67

2358.14–3537.20

589.53

Gamma

Atezolizumab-Bevacizumab, monthly cost (US$)

10,601.35

8481.08–12,721.62

2120.27

Gamma

Sintilimab-Bevacizumab, monthly cost (US$)

4770.82

3816.66–5724.99

954.16

Gamma

Utility PFS

0.76

0.61–0.91

0.15

Normal

Utility PD

0.68

0.54–0.82

0.14

Normal

General ward, cost per cycle (US$)

42.00

33.60–50.40

8.40

Gamma

AE cost

100%

50/200%

75%

Gamma

HCC progression test, cost per test (US$)^a

163.16

130.53–195.79

32.63

Gamma

Proportion of Atezolizumab-Bevacizumab general ward

100%

50%

N/A

N/A

Proportion of Sintilimab-Bevacizumab general ward

100%

50%

N/A

N/A

Cost of subsequent active treatment per patient (US$)

1774.00

1419.20–2128.80

354.80

Gamma

Discount rate

5%

0–8%

N/A

N/A